Islet amyloid polypeptide and diabetes

Current Protein and Peptide Science

Volumn 14, Issue 4, 2013, Pages 330-337

  Westermark, Gunilla T ^a   Westermark, Per ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Amylin; Amyloid; Calcitonin receptor; Fibril; IAPP; Islet amyloid polypeptide; RAMP; Receptor activity modifying proteins; Type 2 diabetes

Indexed keywords

AMYLIN; AMYLIN RECEPTOR; AMYLOID; AMYLOID PROTEIN; CALCITONIN RECEPTOR; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; RECEPTOR ACTIVITY MODIFYING PROTEIN 3; SERUM AMYLOID P;

AMINO ACID SEQUENCE; AMYLOIDOSIS; ARTICLE; BINDING SITE; CELL DEATH; DIABETES MELLITUS; HUMAN; IMMUNOHISTOCHEMISTRY; IMPAIRED BLADDER EMPTYING; INSULIN RESISTANCE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PROTEIN EXPRESSION;

AMYLOID; AMYLOIDOSIS; ANIMALS; DIABETES MELLITUS; HUMANS; ISLET AMYLOID POLYPEPTIDE; ISLETS OF LANGERHANS; RECEPTOR ACTIVITY-MODIFYING PROTEINS; RECEPTORS, CALCITONIN; RECEPTORS, ISLET AMYLOID POLYPEPTIDE;

EID: 84888245583     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/13892037113149990050     Document Type: Article

References (84)

1. Westermark, P.; Wernstedt, C.; Wilander, E.; Sletten, K. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem. Biophys. Res. Commun., 1986, 140, 827-831.
2. Westermark, P.; Wernstedt, C.; Wilander, E.; Hayden, D.W.; O'Brien, T.D.; Johnson, K.H. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc. Natl. Acad. Sci. USA., 1987, 84, 3881-3885.
3. Cooper, G.J.; Willis, A.C.; Clark, A.; Turner, R.C.; Sim, R.B.; Reid, K.B.M. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl. Acad. Sci. USA., 1987, 84, 8628-8632.
4. Opie, E.L. On relation of chronic interstitial pancreatitis to the islands of Langerhans and to diabetes mellitus. J Exp Med., 1901, 5, 397-428.
5. Weichselbaum, A.; Stangl, E. Zur Kenntnis der feineren Veränderungen des Pankreas bei Diabetes mellitus. Wien klin Wochenschr., 1901, 14, 968-972.
6. Warren, S.; LeCompte, P.M.; Legg, M.A. The Pathology of Diabetes Mellitus, Fourth Edition, (Philadelphia: Lea & Febiger), 1966.
7. Sletten, K.; Westermark, P.; Natvig, J.B. Characterization of amyloid fibril proteins from medullary carcinoma of the thyroid. J. Exp. Med., 1976, 143, 993-998.
8. Westermark, P.; Grimelius, L.; Polak, J.M.; Larsson, L.-I.; van Noorden, S.; Wilander, E.; Pearse, A.G.E. Amyloid in polypeptide hormone-producing tumors. Lab. Invest., 1977, 37, 212-215.
9. Westermark, P. Amyloid in the islets of Langerhans: Thoughts and some historical aspects. Ups. J. Med. Sci., 2011, 116, 81-89.
10. Masters, C.; Simms, G.; Weinman, N.A.; Multhaup, G.; McDonald, B.L.; Beyreuther, K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA., 1985, 82, 4245-4249.
11. Cabrera, O.; Berman, D.M.; Kenyon, N.S.; Ricordi, C.; Berggren, P.O.; Caicedo, A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc. Natl. Acad. Sci. USA., 2006, 103, 2334-2339.
12. Betsholtz, C.; Svensson, V.; Rorsman, F.; Engström, U.; Westermark, G.T.; Wilander, E.; Johnson, K.H.; Westermark, P. Islet amyloid polypeptide (IAPP): cDNA cloning and identification of an amyloidogenic region associated with species-specific occurrence of age-related diabetes mellitus. Exp. Cell Res., 1989, 183, 484-493.
13. Nishi, M.; Sanke, T.; Seino, S.; Eddy, R.L.; Fan, Y.-S.; Byers, M.G.; Shows, T.B.; Bell, G.I.; Steiner, D.F. Human islet amyloid polypeptide gene: complete nucleotide sequence, chromosomal localization, and evolutionary history. Mol. Endocrinol., 1989, 3, 1775-1781.
14. Jonas, V.; Lin, C.R.; Kawashima, E.; Semon, D.; Swanson, L.W.; Mermod, J.-J.; Evans, R.M.; Rosenfeld, M.G. Alternative RNA processing events in human calcitonin/calcitonin gene-related peptide gene expression. Proc. Natl. Acad. Sci. USA., 1985, 82, 1994-1998.
15. Toshimori, H.; Narita, R.; Nakazato, M.; Asai, J.; Mitsukawa, T.; Kangawa, K.; Matsuo, H.; Matsukura, S. Islet amyloid polypeptide (IAPP) in the gastrointestinal tract and pancreas of man and rat. Cell Tissue Res., 1990, 262, 401-406.
16. Wang, J.; Xu, J.; Finnerty, J.; Furuta, M.; Steiner, D.F.; Verchere, C.B. The prohormone convertase enzyme 2 (PC2) is essential for processing pro-islet amyloid polypeptide at the NH2-terminal cleavage site. Diabetes, 2001, 50, 534-539.
17. Marzban, L.; Trigo-Gonzalez, G.; Zhu, X.; Rhodes, C.J.; Halban, P.A.; Steiner, D.F.; Verchere, C.B. Role of beta-cell prohormone convertase (PC)1/3 in processing of pro-islet amyloid polypeptide. Diabetes, 2004, 53, 141-148.
18. Smeekens, S.P.; Chan, S.J.; Steiner, D.F. The biosynthesis and processing of neuroendocrine peptides: identification of proprotein convertases involved in intravesicular processing. Prog. Brain Res., 1992, 92, 235-246.
19. Smeekens, S.P.; Montag, A.G.; Thomas, G.; Albiges-Rizo, C.; Carrol, R.; Benig, M.; Phillips, L.A.; Martin, S.; Ohagi, S.; Gardner, P.; Swift, H.H.; Steiner, D.F. Proinsulin processing by the subtilisin-related proprotein convertases furin, PC2, and PC3. Proc. Natl. Acad. Sci. USA., 1992, 89, 8822-8826.
20. Westermark, P.; Li, Z.-C.; Westermark, G.T.; Leckström, A.; Steiner, D.F. Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett., 1996, 379, 203-206.
21. Westermark, P.; Andersson, A.; Westermark, G.T. Islet amyloid polypeptide, islet amyloid and diabetes mellitus. Physiol. Rev., 2011, 91, 795-826.
22. Mather, K.J.; Paradisi, G.; Leaming, R.; Hook, G.; Steinberg, H.O.; Fineberg, N.; Hanley, R.; Baron, A.D. Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity. Diabetes Metab. Res. Rev., 2002, 18, 118-126.
23. Gebre-Medhin, S.; Mulder, H.; Pekny, M.; Zhang, Y.-Z.; Törnell, J.; Westermark, P.; Westermark, G.T.; Sundler, F.; Ahrén, B.; Betsholtz, C. Increased insulin secretion and and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem. Biophys. Res. Commun., 1998, 250, 271-277.
24. Cooper, G.J.S.; Leighton, B.; Dimitriadis, G.D.; Parry-Billings, M.; Kowalchuk, J.M.; Howland, K.; Rothbard, J.B.; Willis, A.C.; Reid, K.B.M. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc. Natl. Acad. Sci. USA., 1988, 85, 7763-7767.
25. Morfis, M.; Tilakaratne, N.; Furness, S.G.; Christopoulos, G.; Werry, T.D.; Christopoulos, A.; Sexton, P.M. Receptor activitymodifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors. Endocrinology, 2008, 149, 5423-5431.
26. Cornish, J.; Callon, K.E.; Bava, U.; Kamona, S.A.; Cooper, G.J.; Reid, I.R. Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone, 2001, 29, 162-168.
27. Dacquin, R.; Davey, R.A.; Laplace, C.; Levasseur, R.; Morris, H.A.; Goldring, S.R.; Gebre-Medhin, S.; Galson, D.L.; Zajac, J.D.; Karsenty, G. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J. Cell Biol., 2004, 164, 509-514.
28. Nakamura, M.; Morimoto, S.; Yang, Q.; Hisamatsu, T.; Hanai, N.; Nakamura, Y.; Mori, I.; Kakudo, K. Osteoclast-like cells express receptor activity modifying protein 2: application of laser capture microdissection. J. Mol. Endocrinol., 2005, 34, 257-261.
29. Young, A. Receptor pharmacology. Adv. Pharmacol., 2005, 52, 47-65.
30. Young, A.A. Brainstem sensing of meal-related signals in energy homeostasis. Neuropharmacology, 2012, 63, 31-45.
31. Chapman, I.; Parker, B.; Doran, S.; Feinle-Bisset, C.; Wishart, J.; Lush, C.; Chen, K.; Lacerte, C.; Burns, C.; McKay, R.; Weyer, C.; Horowitz, M. Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects. Obesity, 2007, 15, 1179-1186.
32. Reidelberger, R.D.; Arnelo, U.; Granqvist, L.; Permert, J. Comparative effects of amylin and cholecystokinin on food intake and gastric emptying in rats. Am. J. Physiol., 2001, 280, R605-R611.
33. Woerle, H.J.; Albrecht, M.; Linke, R.; Zschau, S.; Neumann, C.; Nicolaus, M.; Gerich, J.E.; Göke, B.; Schirra, J. Impaired hyperglycemia-induced delay in gastric emptying in patients with type 1 diabetes deficient for islet amyloid polypeptide. Diabetes Care, 2008, 31, 2325-2331.
34. Heptulla, R.A.; Rodriguez, L.M.; Mason, K.J.; Haymond, M.W. Gastric emptying and postprandial glucose excursions in adolescents with type 1 diabetes. Pediatr. Diabetes, 2008, 9, 561-566.
35. Martínez, A.; Kapas, S.; Miller, M.; Ward, Y.; Cuttitta, F. Coexpression of receptors for adrenomedullin, calcitonin generelated peptide, and amylin in pancreatic beta-cells. Endocrinology, 2000, 141, 406-411.
36. Silvestre, R.A.; Rodríguez-Gallardo, J.; Jodka, C.; Parkes, D.G.; Pittner, R.A.; Young, A.A.; Marco, J. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am. J. Physiol., 2001, 280, E443-E449.
37. Åkesson, B.; Panagiotidis, G.; Westermark, P.; Lundquist, I. Islet amyloid polypeptide inhibits glucagon release and exerts a dual action on insulin release from isolated islets. Regul. Pept., 2003, 111, 55-60.
38. Sipe, J.D.; Benson, M.D.; Buxbaum, J.N.; Ikeda, S.; Merlini, G.; Saraiva, M.J.; Westermark, P. Amyloid fibril protein nomenclature: 2012 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid, 2012, 19, 167-170.
39. Pepys, M.B.; Rademacher, T.W.; Amatayakul-Chantler, S.; Williams, P.; Noble, G.E.; Hutchinson, W.L.; Hawkins, P.N.; Nelson, S.R.; Gallimore, J.R.; Herbert, J.; Hutton, T.; Dwek, R.A. Human serum amyloid P component is an invariant constituent of amyloid deposits and has uniquely homogeneous glycostructure. Proc. Natl. Acad. Sci. USA, 1994, 91, 5602-5606.
40. Bodin, K.; Ellmerich, S.; Kahan, M.C.; Tennent, G.A.; Loesch, A.; Gilbertson, J.A.; Hutchinson, W.L.; Mangione, P.P.; Gallimore, J.R.; Millar, D.J.; Minogue, S.; Dhillon, A.P.; Taylor, G.W.; Bradwell, A.R.; Petrie, A.; Gillmore, J.D.; Bellotti, V.; Botto, M.; Hawkins, P.N.; Pepys, M.B. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature, 2010, 468, 93-97.
41. Kisilevsky, R. Review: Amyloidogenesis-unquestioned answers and unanswered questions. J. Struct. Biol., 2000, 130, 99-108.
42. Goldschmidt, L.; Teng, P.K.; Riek, R.; Eisenberg, D. Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc. Natl. Acad. Sci. USA., 2010, 107, 3487-3492.
43. Eisenberg, D.; Jucker, M. The amyloid state of protein in human diseases. Cell, 2012, 148, 1188-1203.
44. Westermark, P.; Engström, U.; Johnson, K.H.; Westermark, G.T.; Betsholtz, C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. USA., 1990, 87, 5036-5040.
45. Westermark, G.T.; Westermark, P. Localized amyloid important in diseases outside the brain: lessons from the islets of Langerhans and the thoracic aorta. FEBS J., 2011, 278, 3918-3929.
46. Jaikaran, E.T.A.S.; Nilsson, M.R.; Clark, A. Pancreatic [-cell granule peptides form heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation. Biochem. J., 2004, 377, 709-716.
47. Janciauskiene, S.; Eriksson, S.; Carlemalm, E.; Ahrén, B. B cell granule peptides affect human islet amyloid polypeptide (IAPP) fibril formation in vitro. Biochem. Biophys. Res. Commun., 1997, 236, 580-585.
48. Larson, J.L.; Miranker, A.D. The mechanism of insulin action on islet amyloid polypeptide fiber formation. J. Mol. Biol., 2004, 335, 221-231.
49. Sellin, D.; Yan, L.M.; Kapurniotu, A.; Winter, R. Suppression of IAPP fibrillation at anionic lipid membranes via IAPP-derived amyloid inhibitors and insulin. Biophys. Chem., 2010, 150, 73-79.
50. Westermark, P. (1995). Islet amyloid polypeptide and amyloid in the islets of Langerhans. In Diabetes: Clinical Science in Practice, R.D.G. Leslie and D. Robbins, eds. (Cambridge: Cambridge Press University), 189-199.
51. Bell, E.T. Hyalinization of the islets of Langerhans in diabetes mellitus. Diabetes. 1952, 1, 341-344.
52. Ehrlich, J.C.; Ratner, I.M. Amyloidosis of the islets of Langerhans. A restudy of islet hyalin in diabetic and nondiabetic individuals. Am. J. Path., 1961, 38, 49-59.
53. Westermark, P.; Grimelius, L. The pancreatic islet cells in insular amyloidosis in human diabetic and non-diabetic adults. Acta Path. Microbiol. Scand. A., 1973, 81, 291-300.
54. Clark, A.; Wells, C.A.; Buley, I.D.; Cruickshank, J.K.; Vanhegan, R.I.; Matthews, D.R.; Cooper, G.J.S.; Holman, R.R.; Turner, R.C. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diab. Res., 1988, 9, 151-159.
55. Westermark, P. Quantitative studies of amyloid in the islets of Langerhans. Upsala J. Med. Sci., 1972, 77, 91-94.
56. Westermark, P. Fine structure of islets of Langerhans in insular amyloidosis. Virchows Arch. A., 1973, 359, 1-18.
57. Paulsson, J.F.; Andersson, A.; Westermark, P.; Westermark, G.T. Intracellular amyloid-like deposits contain unprocessed pro islet amyloid polypeptide (proIAPP) in beta-cells of transgenic mice overexpressing human IAPP and transplanted human islets. Diabetologia, 2006, 49, 1237-1246.
58. Dyachok, O.; Isakov, Y.; Sågetorp, J.; Tengholm, A. Oscillations of cyclic AMP in hormone-stimulated insulin-secreting beta-cells. Nature, 2006, 439, 349-352.
59. Westermark, G.T.; Gebre-Medhin, S.; Steiner, D.F.; Westermark, P. Islet amyloid development in a mouse strain lacking endogenous islet amyloid polypeptide (IAPP) but expressing human IAPP. Mol. Med., 2000, 6, 998-1007.
60. Jaikaran, E.T.A.S.; Clark, A. Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim. Biophys. Acta., 2001, 1537, 179-203.
61. Westermark, G.T.; Westermark, P.; Nordin, A.; Törnelius, E.; Andersson, A. Formation of amyloid in human pancreatic islets transplanted to the liver and spleen of nude mice. Ups. J. Med. Sci., 2003, 108, 193-204.
62. Yagui, K.; Yamaguchi, T.; Kanatsuka, A.; Shimada, F.; Huang, C.I.; Tokuyama, Y.; Ohsawa, H.; Yamamura, K.; Miyazaki, J.; Mikata, A.; Yoshida, S.; Makino, H. Formation of islet amyloid fibrils in beta-secretory granules of transgenic mice expressing human islet amyloid polypeptide/amylin. Eur. J. Endocrinol., 1995, 132, 487-496.
63. Rochet, J.-C.; Lansbury, P.T.J. Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol., 2000, 10, 60-68.
64. Chiti, F.; Dobson, C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem., 2006, 75, 333-366.
65. Westermark, P.; Wilander, E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia, 1978, 15, 417-421.
66. Höppener, J.W.; Ahrén, B.; Lips, C.J. Islet amyloid and type 2 diabetes mellitus. N. Engl. J. Med., 2000, 343, 411-419.
67. Dobson, C.M. Principles of protein folding, misfolding and aggregation. Sem. Cell Develop. Biol., 2004, 15, 3-16.
68. Lang, D.A.; Matthews, D.R.; Peto, J.; Turner, R.C. Cyclic oscillations of basal plasma glucose and insulin concentrations in human beings. N. Engl. J. Med., 1979, 301, 1023-1027.
69. Ritzel, R.A.; Meier, J.J.; Lin, C.Y.; Veldhuis, J.D.; Butler, P.C. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes, 2007, 56, 65-71.
70. Westermark, P.; Eizirik, D.L.; Pipeleers, D.G.; Hellerström, C.; Andersson, A. Rapid deposition of amyloid in human islets transplanted into nude mice. Diabetologia, 1995, 38, 543-549.
71. de Koning, E.P.J.; Morris, E.R.; Hofhuis, F.M.A.; Posthuma, G.; Höppener, J.W.M.; Morris, J.F.; Capel, P.J.A.; Clark, A.; Verbeek, J.S. Intra-and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proc. Natl. Acad. Sci. USA., 1994, 91, 8467-8471.
72. Westermark, G.T.; Westermark, P.; Eizirik, D.; Hellerström, C.; Fox, N.; Steiner, D.F.; Andersson, A. Differences in amyloid deposition in islets of transgenic mice expressing human islet amyloid polypeptide versus human islets implanted into nude mice. Metabolism, 1999, 48, 448-454.
73. Udayasankar, J.; Kodama, K.; Hull, R.L.; Zraika, S.; Aston-Mourney, K.; Subramanian, S.L.; Tong, J.; Faulenbach, M.V.; Vidal, J.; Kahn, S.E. Amyloid formation results in recurrence of hyperglycaemia following transplantation of human IAPP transgenic mouse islets. Diabetologia, 2009, 52, 145-153.
74. Bohman, S.; Westermark, G.T. Extensive amyloid formation in transplanted microencapsulated mouse and human islets. Amyloid, 2012, 19, 87-93.
75. Westermark, P.; Andersson, A.; Westermark, G.T. Is aggregated IAPP a cause of beta-cell failure in transplanted human pancreatic islets? Curr. Diab. Rep., 2005, 5, 184-188.
76. Westermark, G.T.; Westermark, P.; Berne, C.; Korsgren, O. Widespread amyloid deposition in transplanted human pancreatic islets. N. Engl. J. Med., 2008, 359, 977-979.
77. Westermark, G.T.; Davalli, A.M.; Secchi, A.; Folli, F.; Kin, T.; Toso, C.; Shapiro, A.M.; Korsgren, O.; Tufveson, G.; Andersson, A.; Westermark, P. Further evidence for amyloid deposition in clinical pancreatic islet grafts. Transplantation, 2012, 93, 219-223.
78. Dezso, Z.; Nikolsky, Y.; Sviridov, E.; Shi, W.; Serebriyskaya, T.; Dosymbekov, D.; Bugrim, A.; Rakhmatulin, E.; Brennan, R.J.; Guryanov, A.; Li, K.; Blake, J.; Samaha, R.R.; Nikolskaya, T. A comprehensive functional analysis of tissue specificity of human gene expression. BMC Biol., 2008, 6, 49.
79. Lan, H.; Rabaglia, M.E.; Stoehr, J.P.; Nadler, S.T.; Schueler, K.L.; Zou, F.; Yandell, B.S.; Attie, A.D. Gene expression profiles of nondiabetic and diabetic obese mice suggest a role of hepatic lipogenic capacity in diabetes susceptibility. Diabetes, 2003, 52, 688-700.
80. McLatchie, L.M.; Fraser, N.J.; Main, M.J.; Wise, A.; Brown, J.; Thompson, N.; Solari, R.; Lee, M.G.; Foord, S.M. RAMPs regulate the transport and ligand specificityof the calcitonin-receptor-like receptor. Nature, 1998, 393, 333-339.
81. Yanai, I.; Benjamin, H.; Shmoish, M.; Chalifa-Caspi, V.; Shklar, M.; Ophir, R.; Bar-Even, A.; Horn-Saban, S.; Safran, M.; Domany, E.; Lancet, D.; Shmueli, O. Genome-wide midrange transcription profiles reveal expression level relationships in human tissue specification. Bioinformatics, 2005, 21, 650-659.
82. Uhlén, M.; Oksvold, P.; Fagerberg, L.; Lundberg, E.; Jonasson, K.; Forsberg, M.; Zwahlen, M.; Kampf, C.; Wester, K.; Hober, S.; Wernerus, H.; Björling, L.; Pontén, F. Towards a knowledge-based Human Protein Atlas. Nat. Biotechnol., 2010, 28, 1248-1250.
83. Husmann, K.; Sexton, P.M.; Fischer, J.A.; Born, W. Mouse receptor-activity-modifying proteins 1,-2 and-3: amino acid sequence, expression and function. Mol. Cell. Endocrinol., 2000, 162, 35-43.
84. Guerau-de-Arellano, M.; Mathis, D.; Benoist, C. Transcriptional impact of Aire varies with cell type. Proc. Natl. Acad. Sci. USA., 2008, 105, 14011-14016.